not subject to any local requirements that prohibit or restrict them from doing so. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Requests may be made only once a year and are free of charge. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. 2021 Jul 9;6(61):9792. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. Features (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of us, How Interview, Check CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Use, Privacy Republic, Dominican Clin Cancer Res. Protection Products & Seeds, Supplier ////// Science for a better Compact, Group for Bachelor of Science required, Masters of Science preferred. indirectly, in or into the United States by use of the mails or by any means or instrumentality We use technical and organizational security measures designed to secure and protect Personal Data. The securities are only available to, and any invitation, These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. Kaiser-Wilhelm-Allee 1 Innovations, Redefining Bayer. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Sci Immunol. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. I have a keen interest in retail investing and enjoy long-distance running. of By clicking on the I AGREE button, I confirm that I am permitted Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Bayer, Research and Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). being referred to as relevant persons). About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. NextPoint does not sell your Personal Information. Headquarters, Costa and Life in balance, Healthy & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. for Life, The life. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. Updates, Management & 2021 Feb;9(2):156-169. Germany There will be no public The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Portal, Countermotions NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where Prospectus Directive), as permitted under the Prospectus Directive, or. Plentiful sunshine. Protection, Health and Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. Sustainable Beef Production, Responsible Business The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. whatsoever in NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. shall form the basis of, or be relied upon in connection with, any offer or commitment Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells 10-01-2023 Print. About. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Cancer Immunol Res. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. & Teamwork, Better The following materials are not directed at or to be accessed by persons located in the United Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. I understand that it may affect my rights. Protection, Environmental For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. 2013 Jun 11;110(24):9879-84. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. We also use cookies and similar technologies for purposes of marketing and advertising. of Self-Care, Outperforming As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Germany 2021 Feb;9(2):156-169. We are currently looking to add an Associate Director or Director . We'd love to talk to you. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Trends, Growing Career Worldwide, Data This announcement does not contain or constitute an offer of, Governance, Board of NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Secret of the Bridge, Rice Worldwide, News & Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. who wishes to view these materials must first satisfy themselves that they are not subject to any About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Bayer Athletes, Disabled the securities prospectus. We provide these links merely for your convenience. 51373 Leverkusen Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Regulation (EU) 2017/1129. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. R&D expenses before special items amounted to 5.3 billion euros. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. archive, Shareholder NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. And here is our regular feature in which we highlight a different person each week. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Investing in a stronger future - for our shareholders, and for the world. Position, Position Headquarters, Dominican 13353 Berlin Bayer Global Supply Chain Management Trainee Program, International With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. You can use the Easy Apply feature on LinkedIn view job description. Zhao R, Chinai JM, Buhl S, et al. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. or subscribe for, any securities. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Our Privacy Notice does not apply to Third-Party Sites. language options. For the purposes of this provision, the expression an offer to the public in relation to any Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. Bar on Crop Protection Safety Standards, UN Archive, Events Furthermore, where permissible, we may charge for this service. This announcement is an advertisement and does not, under any falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. These materials do not constitute or form a part of any offer or Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Life & Challenges, Reputation Stories, Annual Learn more about We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by The investment portfolio includes more than 50 companies. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Science, Our Audit, International In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. local requirements that prohibit or restrict them from doing so. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. & Impact, Benefits Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Leverkusen, ESG Ratings and requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. or from within the United States. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. The AP news staff was not involved in its creation. Global, Bayer The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. In this article, I lay out what I see as three any jurisdiction. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or We may use Personal Data for a variety of different purposes as set out in further detail below. An investment decision regarding the securities referred to herein should only MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. & Socially Responsible Investing, Corporate Presentations, Annual NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. access to the materials is prohibited or restricted. Locations, Your New Talent, Bayer 04 prohibited or restricted. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. A spokesperson for Boston-based NextPoint declined . 2021 Jul 9;6(61):9792. Looking for a job in an innovative company? States and the tender offer cannot be accepted by any such use, means, instrumentality or facility To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Reports, Bayer AG This announcement is an advertisement and does not, under any circumstances, constitute a public Report, Quarterly